$287 Million is the total value of Opaleye Management Inc.'s 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HROW | Buy | HARROW HEALTH INC | $55,719,000 | +38.1% | 3,775,000 | +12.9% | 19.38% | +16.2% |
| TELA | Buy | TELA BIO INC | $23,837,350 | +37.4% | 2,072,813 | +1.8% | 8.29% | +15.7% |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $21,403,200 | +7.9% | 735,000 | -9.3% | 7.44% | -9.2% |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $17,070,750 | -36.4% | 6,075,000 | -6.0% | 5.94% | -46.4% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $13,395,600 | +1.6% | 732,000 | +9.0% | 4.66% | -14.5% |
| CYTK | Sell | CYTOKINETICS INC | $11,455,000 | -10.1% | 250,000 | -4.9% | 3.98% | -24.3% |
| KROS | Sell | KEROS THERAPEUTICS INC | $11,428,760 | -5.4% | 238,000 | -25.9% | 3.97% | -20.4% |
| PCVX | Sell | VAXCYTE INC | $8,487,150 | +86.1% | 177,000 | -6.8% | 2.95% | +56.7% |
| New | BIOHAVEN LTD | $7,495,200 | – | 540,000 | +100.0% | 2.61% | – | |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS INC | $7,329,300 | +159.9% | 330,000 | -5.9% | 2.55% | +118.8% |
| TARA | Sell | PROTARA THERAPEUTICS INC | $7,216,152 | -9.7% | 2,692,594 | -0.6% | 2.51% | -24.0% |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $6,839,100 | -2.3% | 4,590,000 | +9.5% | 2.38% | -17.7% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $6,442,800 | +21.2% | 1,560,000 | -6.1% | 2.24% | +2.0% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $6,240,832 | – | 923,200 | +100.0% | 2.17% | – |
| ETON | Sell | ETON PHARMACEUTICALS INC | $6,119,400 | +15.6% | 2,170,000 | -13.9% | 2.13% | -2.7% |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $5,465,916 | -12.5% | 611,400 | -3.7% | 1.90% | -26.3% |
| PRQR | Sell | PROQR THERAPEUTICS NV | $5,402,000 | +133.0% | 1,460,000 | -53.1% | 1.88% | +96.2% |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $4,684,350 | – | 417,500 | +100.0% | 1.63% | – |
| XOMA | Sell | XOMA CORP DEL | $4,471,200 | +0.7% | 243,000 | -2.0% | 1.56% | -15.3% |
| CDXS | Sell | CODEXIS INC | $4,461,950 | -36.2% | 957,500 | -17.1% | 1.55% | -46.3% |
| URGN | Buy | UROGEN PHARMA LTD | $4,334,379 | +31.1% | 488,656 | +22.9% | 1.51% | +10.3% |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $4,281,994 | – | 1,206,841 | +100.0% | 1.49% | – |
| Buy | ASTRIA THERAPEUTICS INC | $3,896,758 | +222.8% | 261,703 | +96.0% | 1.36% | +172.1% | |
| LQDA | Sell | LIQUIDIA CORPORATION | $3,567,200 | +16.4% | 560,000 | -0.6% | 1.24% | -2.1% |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $3,373,450 | – | 167,500 | +100.0% | 1.17% | – |
| New | MARINUS PHARMACEUTICALS INC | $3,288,276 | – | 826,200 | +100.0% | 1.14% | – | |
| EDAP | Buy | EDAP TMS S Asponsored adr | $3,269,561 | +456.0% | 306,713 | +330.2% | 1.14% | +367.9% |
| New | AADI BIOSCIENCE INC | $3,233,750 | – | 252,046 | +100.0% | 1.12% | – | |
| MOR | Buy | MORPHOSYS AGsponsored ads | $3,209,828 | +427.1% | 896,600 | +640.9% | 1.12% | +342.9% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $2,695,600 | -55.7% | 460,000 | -48.9% | 0.94% | -62.7% |
| Buy | THESEUS PHARMACEUTICALS INC | $2,664,300 | +108.1% | 535,000 | +142.5% | 0.93% | +75.0% | |
| FENC | New | FENNEC PHARMACEUTICALS INC | $2,613,120 | – | 272,200 | +100.0% | 0.91% | – |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $2,521,996 | +11363.6% | 138,800 | +9153.3% | 0.88% | +9644.4% |
| STXS | Sell | STEREOTAXIS INC | $2,452,950 | -12.5% | 1,185,000 | -23.9% | 0.85% | -26.3% |
| BCAB | New | BIOATLA INC | $2,159,850 | – | 261,800 | +100.0% | 0.75% | – |
| FBIO | Sell | FORTRESS BIOTECH INC | $1,342,750 | -47.9% | 2,050,000 | -31.6% | 0.47% | -56.2% |
| ALLK | ALLAKOS INC | $1,292,470 | +37.6% | 153,500 | 0.0% | 0.45% | +15.7% | |
| TBPH | New | THERAVANCE BIOPHARMA INC | $982,872 | – | 87,600 | +100.0% | 0.34% | – |
| TRVI | New | TREVI THERAPEUTICS INC | $936,050 | – | 485,000 | +100.0% | 0.33% | – |
| Sell | MODULAR MEDICAL INC | $490,000 | -56.8% | 245,000 | -11.0% | 0.17% | -63.8% | |
| BLRX | Exit | BIOLINERX LTDsponsored ads | $0 | – | -16,667 | -100.0% | -0.01% | – |
| MGTX | Exit | MEIRAGTX HLDGS PLC | $0 | – | -10,000 | -100.0% | -0.04% | – |
| OPTN | Exit | OPTINOSE INC | $0 | – | -90,970 | -100.0% | -0.14% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -575,000 | -100.0% | -0.15% | – |
| LUMO | Exit | LUMOS PHARMA INC | $0 | – | -46,576 | -100.0% | -0.17% | – |
| NPCE | Exit | NEUROPACE INC | $0 | – | -116,324 | -100.0% | -0.18% | – |
| Exit | JOURNEY MEDICINE CORP | $0 | – | -259,293 | -100.0% | -0.26% | – | |
| CMRX | Exit | CHIMERIX INC | $0 | – | -365,000 | -100.0% | -0.29% | – |
| IMPL | Exit | IMPEL PHARMACEUTICALS INC | $0 | – | -255,250 | -100.0% | -0.51% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -577,250 | -100.0% | -0.76% | – |
| MRUS | Exit | MERUS N.V. | $0 | – | -253,200 | -100.0% | -2.10% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -292,700 | -100.0% | -2.17% | – |
| CUTR | Exit | CUTERA INC | $0 | – | -147,700 | -100.0% | -2.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.